Stock Market News News 20 December 2025

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (Nasdaq: FOLD) has effectively become a “deal stock” — the market is now trading the shares primarily on the odds and timing of a takeover rather than on classic biotech catalysts.

21 December 2025

Biotech Industry·Company Updates·Investment Analysis·Mergers and Acquisitions·Stock Market News

Verizon Stock (VZ) News Today: Frontier Deal Approvals, 5G Tower Partnership, Dividend Outlook and 2026 Catalysts (Dec. 21, 2025)

Verizon Communications Inc. (NYSE: VZ) heads into the final full trading week of 2025 with investors focused on two big themes: the march toward closing its Frontier Communications acquisition and the company’s push to keep network investment efficient while protecting

21 December 2025

5G Technology·Investment Trends·Stock Market News

Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has become one of the most closely watched rare-disease stocks heading into the final stretch of 2025 after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at about $4.8

21 December 2025

Biotech Industry·Investment Analysis·Mergers and Acquisitions·Stock Market News

Philip Morris International (PM) Stock News Today: Dividend, FDA Catalysts, and Wall Street Forecasts as of Dec. 20, 2025

Updated: December 20, 2025 — Philip Morris International Inc. (NYSE: PM) stock is ending the week in the spotlight as investors balance a resilient dividend story with a fast-moving U.S. “smoke-free” growth narrative built around ZYN nicotine pouches and the

20 December 2025

Dividend Investing·FDA Updates·Stock Market News·Wall Street Analysis

Intuit (INTU) Stock News, Forecasts and Analyst Outlook: USDC Stablecoin Deal, TurboTax 2026 Tax Push, and Key Catalysts (Dec. 20, 2025)

Dec. 20, 2025 — Intuit Inc. (NASDAQ: INTU) enters the weekend with investors balancing a fresh fintech headline—Intuit’s newly announced USDC stablecoin partnership with Circle—against the familiar seasonal catalyst that often defines the stock’s narrative: TurboTax demand heading into the

20 December 2025

Financial Forecasts·Investment Analysis·Stock Market News

Adobe Stock (ADBE) News on Dec. 20, 2025: Earnings, AI Firefly Expansion, Runway & ChatGPT Deals, Analyst Price Targets, and Lawsuit Risk

Adobe Inc. (NASDAQ: ADBE) heads into the final full week before year-end with a familiar split-screen story for investors: record results and upbeat fiscal 2026 targets on one side, and growing debate over AI-era competition and legal risk on the

20 December 2025

Artificial Intelligence·Financial Analysis·Legal Issues·Stock Market News

Semiconductor Stocks News (Dec. 20, 2025): Micron’s AI Memory Boom, Nvidia “Cheap” Valuation Calls, and the 2026 Outlook

December 20, 2025 — Semiconductor stocks are heading into the final stretch of 2025 with a familiar mix of powerful tailwinds and stubborn risks. On one side: accelerating AI infrastructure demand, a tightening memory market, and a renewed capex cycle

20 December 2025

AI Technology·Investment Insights·Market Outlook·Semiconductor Industry·Stock Market News

Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

As of Saturday, December 20, 2025, investors are digesting a busy stretch of developments around Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)—from Nasdaq-100 index inclusion (effective Dec. 22) to fresh reimbursement tailwinds in the U.K. and continued focus on Amvuttra (vutrisiran) as

20 December 2025

Analyst Opinions·Biotech Stocks·Financial Forecasts·Investment Analysis·Stock Market News

Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

December 20, 2025 — Amgen Inc. (NASDAQ: AMGN) is closing out the year with a rare combination of near-term policy headlines and company-specific catalysts that matter to investors: a new U.S. drug-pricing deal tied to the TrumpRx rollout, fresh FDA

20 December 2025

Dividend Updates·FDA Approvals·Investment Analysis·Pharmaceuticals·Stock Market News

AppLovin (APP) Stock Update Dec. 20, 2025: Why Shares Are Surging, Fresh Analyst Targets, and the Next Catalysts

AppLovin Corporation (NASDAQ: APP) has become one of the market’s most closely watched adtech and AI-driven marketing stories—especially as investors debate how much runway remains in its e-commerce expansion and how durable its mobile gaming advertising strength will be into

20 December 2025

Analyst Ratings·Financial Updates·Investment Analysis·Stock Market News·Tech Stocks

CoreWeave (CRWV) Stock News and Forecasts for Dec. 20, 2025: DOE “Genesis Mission” Boosts Shares as Analysts Debate AI Data-Center Risks

CoreWeave, Inc. (NASDAQ: CRWV) ends the week back in the spotlight after a sharp Friday rebound that partially reversed a bruising late-2025 selloff. As of the Dec. 19, 2025 close (the last trading session ahead of Dec. 20), CoreWeave shares

20 December 2025

AI Technology·Data Centers·Financial Forecasts·Investment Analysis·Stock Market News

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine, Inc. (NASDAQ: IRON) stock is seeing a classic “biotech catalyst storm” on Dec. 20, 2025: big intraday swings, headline-driven volatility, and analysts arguing over whether the market is repricing risk or merely repricing uncertainty. As of the latest

20 December 2025

Biotech Stocks·FDA Updates·Financial Forecasts·Investment Analysis·Stock Market News

Stock Market News News 20 December 2025 - 21 December 2025